Literature DB >> 2988431

Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime.

Y Ninomiya, M Aoyama, I Umeda, Y Suhara, H Ishitsuka.   

Abstract

Modes of action of five antirhinovirus agents were compared. Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731 were active preferentially against human rhinovirus. Serotypes of the virus varied in their susceptibility to these three agents, whereas Ro 09-0179 and enviroxime showed activity against all the serotypes of the virus tested to date. Ro 09-0410, RMI-15,731, and 4',6-dichloroflavan inactivated the virus directly, although 4',6-dichloroflavan did so only slightly. Inactivation by 4',6-dichloroflavan and RMI-15,731 was associated with the binding of the agents to the virus, since the infectivity, reduced by exposure to the agents, was restored to the original level by extraction of the agents with chloroform. The binding of [3H]Ro 09-0410 to human rhinovirus type 2 was inhibited by unlabeled Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731 but not by Ro 09-0179 or enviroxime. Furthermore, subtypes resistant to both 4',6-dichloroflavan and RMI-15,731 showed cross-resistance to Ro 09-0410 and vice versa. On the other hand, sublines resistant to these three agents were not cross-resistant to Ro 09-0179 or enviroxime. These results indicate (i) that Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731 exert their activities through the same mode of action, namely, binding to or interaction with some specific site on the viral capsid protein, and (ii) that the binding or interaction sites for these three agents are either the same or very close to each other.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988431      PMCID: PMC180102          DOI: 10.1128/AAC.27.4.595

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Fractionation of biologically active and inactive populations of human rhinovirus type 2.

Authors:  B D Korant; K Lonberg-Holm; F H Yin; J Noble-Harvey
Journal:  Virology       Date:  1975-02       Impact factor: 3.616

2.  A physico-chemical sub-grouping of the mammalian picornaviruses.

Authors:  J F Newman; D J Rowlands; F Brown
Journal:  J Gen Virol       Date:  1973-02       Impact factor: 3.891

Review 3.  Rhinoviruses.

Authors:  E J Stott; R A Killington
Journal:  Annu Rev Microbiol       Date:  1972       Impact factor: 15.500

4.  Early interaction of rhinoviruses with host cells.

Authors:  K Lonberg-Holm; B D Korant
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

5.  Antigenic determinants of infective and inactivated human rhinovirus type 2.

Authors:  K Lonberg-Holm; F H Yin
Journal:  J Virol       Date:  1973-07       Impact factor: 5.103

6.  Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.

Authors:  J H Wikel; C J Paget; D C DeLong; J D Nelson; C Y Wu; J W Paschal; A Dinner; R J Templeton; M O Chaney; N D Jones; J W Chamberlin
Journal:  J Med Chem       Date:  1980-04       Impact factor: 7.446

7.  Inhibition of rhinovirus replication in in organ culture by a potential antiviral drug.

Authors:  D C DeLong; S E Reed
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

8.  Antipicornavirus flavone Ro 09-0179.

Authors:  H Ishitsuka; C Ohsawa; T Ohiwa; I Umeda; Y Suhara
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.

Authors:  Y Ninomiya; C Ohsawa; M Aoyama; I Umeda; Y Suhara; H Ishitsuka
Journal:  Virology       Date:  1984-04-30       Impact factor: 3.616

10.  4',6-Dichloroflavan (BW683C), a new anti-rhinovirus compound.

Authors:  D J Bauer; J W Selway; J F Batchelor; M Tisdale; I C Caldwell; D A Young
Journal:  Nature       Date:  1981-07-23       Impact factor: 49.962

View more
  8 in total

1.  Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 2.  Chemotherapy of rhinovirus colds.

Authors:  S J Sperber; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

3.  Antirhinovirus compound 44,081 R.P. inhibits virus uncoating.

Authors:  B Alarcon; A Zerial; C Dupiol; L Carrasco
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

4.  Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.

Authors:  P R Wyde; H R Six; S Z Wilson; B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

5.  In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords; K van Eemeren; R Stokbroekx; P A Janssen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

6.  In vitro activity of R 61837, a new antirhinovirus compound.

Authors:  K Andries; B Dewindt; M De Brabander; R Stokbroekx; P A Janssen
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

Review 7.  Antiviral Potential of Selected Medicinal Herbs and Their Isolated Natural Products.

Authors:  W P R T Perera; Janitha A Liyanage; K G C Dissanayake; Hiruni Gunathilaka; W M T D N Weerakoon; D N Wanigasekara; W S K Fernando; R M H Rajapaksha; R P Liyanage; Bingun T Perera
Journal:  Biomed Res Int       Date:  2021-12-08       Impact factor: 3.411

Review 8.  The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.

Authors:  Judith M Rollinger; Michaela Schmidtke
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.